VIMRxyn: Will begin an NIH-sponsored oral dose Phase I/II trial by the end of 1993

VimRx Pharmaceuticals Inc. (VMRX) Product: VIMRxyn, hypericin-based antiviral Indication: Treatment of HIV/AIDS Status: Will begin an NIH-sponsored oral dose Phase I/II trial by the end of 1993 Note:...